Journal of Immunology Research / 2018 / Article / Tab 4

Research Article

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients

Table 4

Univariate analysis of overall survival.

VariablenOR [95% CI] value

Clinical data
 Breslow index (mm)101.13 [0.7514–1.718]0.545
 PS > 0103.448 [0.67–17.6]0.137
 LDH > N101.3 [0.32–5.4]0.716
 AJCC stage IV100.81 [0.198–3.28]0.763
 Metastatic disease diagnosis to TIL infusion (years)101.01 [0.835–1.23]0.887
 Ipilimumab before TILs101.1 [0.26–4.57]0.913
 Ipilimumab after TILs100.59 [0.12–2.98]0.526
 TILs infused (×109)101.04 [0.94–1.16]0.449
BRAF mutation V600E90.38 [0.07–2.03]0.260
 c-KIT mutated103.97 [0.36–43.9]0.261
Melanoma cell PCR
 MAGE-170.41 [0.04–4.68]0.476
 MAGE-371.04 [0.11–9.66]0.503
 Melan-A717.5 [0.21–1483]0.207
 NY-ESO-16NA0.999
 Na17A79.58 [0.22–411]0.239
 gp10070.86 [0.04–16.8]0.923
 Tyrosinase7NA0.998
TIL phenotypes
 CD3+9NA0.643
 CD3 + CD4+93.15 [0.28–35.6]0.355
 CD3 + CD8+94.78 [0.14–166]0.388
 CD4 + CD25+9NA0.071
 CD4 + CD25 + CD127lowCTLA4+90.97 [0.02–57.97]0.987
 CD4 + CD25 + CD127lowFoxp3+916E7 [43.4–6E12]0.011

AJCC: American Joint Committee on Cancer; CI: confidence interval; LDH: lactate dehydrogenase; MAGE-1 and -3: melanoma antigen-1 and -3; NA: data not available; NY-ESO1: New York esophageal squamous cell carcinoma 1; PS: performance status. Significant value.